78 related articles for article (PubMed ID: 15300676)
1. Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride.
Meisel A; Winter C; Zschenderlein R; Arnold G
Mov Disord; 2004 Aug; 19(8):991-2. PubMed ID: 15300676
[No Abstract] [Full Text] [Related]
2. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
Scahill L; Blair J; Leckman JF; Martin A
J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
[No Abstract] [Full Text] [Related]
3. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Ratner Y; Gibel A; Yorkov V; Ritsner MS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1401-9. PubMed ID: 17669574
[TBL] [Abstract][Full Text] [Related]
5. Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats.
Fell MJ; Gibson R; McDermott E; Sisodia G; Marshall KM; Neill JC
Behav Brain Res; 2005 May; 160(2):338-43. PubMed ID: 15863230
[TBL] [Abstract][Full Text] [Related]
6. Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome.
Degrauw RS; Li JZ; Gilbert DL
Pediatr Neurol; 2009 Sep; 41(3):183-6. PubMed ID: 19664533
[TBL] [Abstract][Full Text] [Related]
7. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
Olié JP; Spina E; Murray S; Yang R
Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
[TBL] [Abstract][Full Text] [Related]
8. Ziprasidone--not an option for serotonin syndrome.
Cates ME
CMAJ; 2003 Nov; 169(11):1147-8. PubMed ID: 14638642
[No Abstract] [Full Text] [Related]
9. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels.
Mauri MC; Colasanti A; Rossattini M; Volonteri LS; Dragogna F; Fiorentini A; Fiorentini A; Valli A; Papa P
Pharmacopsychiatry; 2007 May; 40(3):89-92. PubMed ID: 17541882
[TBL] [Abstract][Full Text] [Related]
10. A prospective open-label treatment trial of ziprasidone monotherapy in children and adolescents with bipolar disorder.
Biederman J; Mick E; Spencer T; Dougherty M; Aleardi M; Wozniak J
Bipolar Disord; 2007 Dec; 9(8):888-94. PubMed ID: 18076539
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Kostulski A; Wyszogrodzka-Kucharska A; Rabe-Jabłońska J
Przegl Lek; 2005; 62(9):938-43. PubMed ID: 16541734
[TBL] [Abstract][Full Text] [Related]
12. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs.
Ondo WG; Jong D; Davis A
J Child Neurol; 2008 Apr; 23(4):435-7. PubMed ID: 18192650
[TBL] [Abstract][Full Text] [Related]
13. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
[TBL] [Abstract][Full Text] [Related]
14. Ziprasidone: a novel psychotropic with unique properties.
Ballas C; Yang C; O'Reardon J; Ballas P; Baldassano C
Expert Rev Neurother; 2004 Mar; 4(2):179-86. PubMed ID: 15853558
[TBL] [Abstract][Full Text] [Related]
15. Ziprasidone therapy for post-traumatic stress disorder.
Siddiqui Z; Marcil WA; Bhatia SC; Ramaswamy S; Petty F
J Psychiatry Neurosci; 2005 Nov; 30(6):430-1. PubMed ID: 16327877
[TBL] [Abstract][Full Text] [Related]
16. [Ziprasidone as coadjuvant treatment in resistant obsessive-compulsive disorder treatment].
Iglesias Garcia C; Santamarina Montila S; Alonso Villa MJ
Actas Esp Psiquiatr; 2006; 34(4):277-9. PubMed ID: 16823689
[TBL] [Abstract][Full Text] [Related]
17. [Ziprasidone and dementia].
Aakhus E
Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2155-6; author reply 2155-6. PubMed ID: 15334150
[No Abstract] [Full Text] [Related]
18. Ziprasidone-associated pedal edema in the treatment of schizophrenia.
Ku HL; Su TP; Chou YH
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):963-4. PubMed ID: 16624468
[TBL] [Abstract][Full Text] [Related]
19. Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.
Kalinichev M; Rourke C; Jones DN
Behav Pharmacol; 2006 May; 17(3):289-92. PubMed ID: 16572006
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of extrapyramidal hyperkineses in childhood with tiapride].
Klepel H; Gebelt H; Koch RD; Tzenow H
Psychiatr Neurol Med Psychol (Leipz); 1988 Sep; 40(9):516-22. PubMed ID: 3070595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
